DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Solomon BJ, Bauer TM, Felip E. et al.
Safety and efficacy of lorlatinib (PF-06463922) from the dose escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).
J Clin Oncol 2016;
34 (Suppl. 01) 9009-9009
Access:
We do not assume any responsibility for the contents of the web pages of other providers.